Neuropathy treatment runs in two gears: treat the cause and treat the symptoms. Symptomatic relief alone, without addressing etiology, leaves the disease advancing underneath.
Treating the cause
Metabolic and endocrine causes come first because they are common. Glycemic control slows diabetic polyneuropathy but does not reverse established damage, and blood pressure, lipid, and smoking control matter equally. Dialysis and transplantation address uremic disease, and hormone replacement reverses hypothyroid neuropathy.
Toxic and deficiency causes require removing the trigger: alcohol, offending drugs, solvents, and dose adjustment of chemotherapy where possible. What can and cannot be done to prevent chemotherapy-induced neuropathy is covered under chemotherapy-induced neuropathy. Deficient vitamins are replaced, with one paradox to remember: vitamin B6 deficiency causes neuropathy, but excess B6 causes a sensory ataxia of its own, so supplementation is dosed rather than open-ended.
Infections are treated directly: antibiotics for Lyme disease and leprosy multidrug regimens, antivirals for HIV, and hepatitis C therapy, which also addresses cryoglobulinemic disease.
Immune causes follow disease-specific protocols. Guillain-Barre syndrome receives intravenous (IV) immunoglobulin or plasma exchange, never steroids alone; the full protocol sits under Guillain-Barre syndrome. CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) answers to steroids, immunoglobulin, and plasma exchange, often as maintenance. Vasculitis needs steroids plus immunosuppression such as cyclophosphamide in severe disease. Paraneoplastic disease is treated through the tumor with plasma exchange as adjunct.
Hereditary disease is mostly supportive. Transthyretin amyloidosis is the exception with real options: historical liver transplantation plus current stabilizer, gene-silencing, and antisense therapies. Charcot-Marie-Tooth disease is managed with physiotherapy and orthotics, and hereditary pressure-palsy disease by avoiding pressure, since neither answers to immunotherapy.
The table gathers these directions by category.
| Category | Condition | Treatment direction |
|---|---|---|
| Hereditary | Transthyretin amyloidosis | Transplantation history; stabilizer, silencing, and antisense options |
| Hereditary | Charcot-Marie-Tooth disease | Physiotherapy and orthotics |
| Endocrine | Diabetes, uremia, hypothyroidism | Glycemic and vascular control; dialysis or transplant; hormone replacement |
| Toxic or deficiency | Alcohol, drugs, solvents, vitamin deficiency | Remove exposure; replace B1, B6, B12, folate, E |
| Infectious | HIV, hepatitis C, leprosy, Lyme disease | Antiretrovirals; hepatitis therapy; multidrug antibiotics |
| Inflammatory | CIDP, IgM gammopathy, vasculitis, paraneoplastic | Steroids, immunoglobulin, or exchange; rituximab or exchange for IgM disease; immunosuppression; tumor treatment |
What not to do
Four negatives prevent real harm:
- Steroids have no place in multifocal motor neuropathy and may worsen it.
- Hereditary neuropathies do not answer to immunotherapy.
- Diabetic symmetric polyneuropathy is metabolic rather than immune-mediated, so immunotherapy is not its treatment.
- Stable, slowly progressive, sensory-predominant polyneuropathy in older patients with a negative basic workup does not warrant endless investigation; genetic testing may clarify atypical cases, but the yield of repeating the same search is low.
Treating neuropathic pain
Neuropathic pain does not answer to ordinary analgesics the way nociceptive pain does. The first-line drugs, their doses, and how to switch or combine them are covered under neuropathic pain, where pain control runs alongside the search for and treatment of the underlying cause.